Aspire-Lakewood Holdings, Inc.

What they do

Aspire develops novel sublingual delivery technology for known drugs, initially focusing on a high-dose aspirin product for myocardial infarction. It outsources manufacturing to third parties like Glatt and Microsize, and has completed a Phase 1-style clinical trial in Florida to support a 505(b)(2) NDA submission. The company also plans to market nutraceuticals using the same delivery technology, but has no licensing or collaboration agreements yet.

Revenue drivers

• Instaprin (sublingual aspirin) — Planned 505(b)(2) NDA for high-dose sublingual aspirin; clinical trial completed July 2025, NDA submission planned for late 2026. No commercial sales yet.
• Nutraceuticals — Company expects to generate revenue from marketing drugs and nutraceuticals using sublingual delivery; no specific products or sales reported.
• Licensing/Collaboration agreements — Future potential source of revenue via development funding and milestones, but currently has no such agreements.

Recent performance

For the year ended December 31, 2025, revenue was $6,202, net loss was $24.5M, and diluted EPS was -$16.38. Operating cash flow for 2025 was -$4.9M. Quarterly revenue has been minimal: $1,941 (Sept 2025), $28,353 (Mar 2026), $63,104 (Jun 2026). As of June 30, 2026, total assets were $13.5M, cash and equivalents $12.2M, total liabilities $1.8M, and shareholder equity $11.8M.

Strategy

Aspire plans to submit a 505(b)(2) NDA for its sublingual aspirin in late 2026, leveraging the positive PK trial results. It will continue to contract manufacturing and has added Microsize as a CDMO for the next round of clinical trials. The company also completed the acquisition of Dura Drive Control Systems (DCS) in August 2026 to add automotive control systems, broadening beyond biopharma. Management expects revenue from product sales and potential licensing deals, but has not established sales/marketing infrastructure.

Risks

• Limited operating history — Aspire is an early-stage company formed in 2025 with no approved products, making evaluation difficult.
• Recurring net losses — The company has incurred net losses in every year since inception and expects substantial losses ahead.
• Need for additional capital — Requires substantial financing to achieve goals; failure to raise capital could delay or terminate development.
• Key personnel and legal issues — Former CEO of Instaprin Pharmaceuticals was convicted of securities fraud conspiracy; success depends on retaining skilled leadership.

Outlook

Management expects to file a 505(b)(2) NDA for high-dose sublingual aspirin in late 2026. The acquisition of DCS in August 2026 is expected to contribute revenues, earnings, and cash flow. There are no licensed or partnered products yet, and commercial manufacturing capacity may need to be expanded with additional suppliers.